Featured Research

from universities, journals, and other organizations

Killing 'Angry' Immune Cells In Fat Could Fight Diabetes

Date:
October 8, 2008
Source:
Cell Press
Summary:
By killing off "angry" immune cells that take up residence in obese fat and muscle tissue, researchers have shown that they can rapidly reverse insulin resistance in obese mice. The findings suggest that treatments aimed at specific subsets of the so-called macrophage cells might offer a very effective new anti-diabetic therapy, according to the researchers.

By killing off "angry" immune cells that take up residence in obese fat and muscle tissue, researchers have shown that they can rapidly reverse insulin resistance in obese mice. The findings reported in the October Cell Metabolism, suggest that treatments aimed at specific subsets of the so-called macrophage cells might offer a very effective new antidiabetic therapy, according to the researchers.

" We used a genetic 'trick' that allowed us to rapidly kill these macrophages," said Jerrold Olefsky of the University of California, San Diego. "The treatment killed these cells within hours, and insulin resistance simply reversed itself. It argues strongly that macrophages are causative for the inflammation that leads to diabetes [in those who are obese]."

" The most interesting thing is that this reversal occurs very rapidly," added Jaap Neels of INSERM in France, who led the work while in Olefsky's lab. "Twenty-four hours later the animals' insulin response had completely normalized. They were still obese, but no longer insulin resistant."

Of course, Neels said, the strategy used in the obese mice wouldn't translate to the clinic directly. It's also unclear whether or not it is the same subtype of macrophage cells that invade fat tissue in people who are obese. Nevertheless, the findings suggest that you would not necessarily need to target all macrophages to have a beneficial effect on the diseases associated with obesity. That's critical because "you don't want to knock out the whole immune system."

Over the past decade, it has become quite clear that obesity gives rise to a state of chronic, low-grade inflammation that contributes to insulin resistance and type 2 diabetes, the researchers explained.

Olefsky and Neels' team along with others recently found that a specific subset of macrophages invades obese fat and muscle tissue. Although little was known about them, those macrophages are defined by a CD11c marker expressed on their surfaces. They also produce high levels of proinflammatory chemicals that are linked to the development of obesity-associated insulin resistance.

In the new study, the researchers tested the idea that killing those cells would reverse the inflammatory symptoms that come with obesity using a mouse model developed earlier in which the CD11c-expressing macrophages were artificially made susceptible to diphtheria toxin.

They found that treatment with the toxin not only reversed the animals' resistance to insulin, but also led to a marked decline in inflammatory signs through the body. The treated animals showed a decline in the CD11c macrophages in both fat and muscle, they confirmed.

" It shows that high triglycerides in muscle don't necessarily have to lead to insulin resistance as it has been thought—as long as the high lipid levels aren't accompanied by inflammation," Neels said.

The obese mice also had less fat in their livers, an important find given the epidemic of obesity-associated fatty liver disease.

If a unique marker can be identified on the macrophages found in human fat tissue, a drug could be designed to take advantage of those features to bind and kill them, Neels said. Alternatively, it may be possible to convert the macrophage cells into another, less inflammatory type.

The researchers include David Patsouris, University of California, San Diego, La Jolla, CA; Ping-Ping Li, University of California, San Diego, La Jolla, CA; Divya Thapar, University of California, San Diego, La Jolla, CA; Justin Chapman, Pfizer Inc., San Diego, CA; Jerrold M. Olefsky, University of California, San Diego, La Jolla, CA; and Jaap G. Neels, University of California, San Diego, La Jolla, CA.


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Cite This Page:

Cell Press. "Killing 'Angry' Immune Cells In Fat Could Fight Diabetes." ScienceDaily. ScienceDaily, 8 October 2008. <www.sciencedaily.com/releases/2008/10/081007123642.htm>.
Cell Press. (2008, October 8). Killing 'Angry' Immune Cells In Fat Could Fight Diabetes. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/10/081007123642.htm
Cell Press. "Killing 'Angry' Immune Cells In Fat Could Fight Diabetes." ScienceDaily. www.sciencedaily.com/releases/2008/10/081007123642.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins